Financial Data and Key Metrics Changes - Revenue for the second quarter was $2,530,000,000, up 5% on a reported basis and 4% on an organic basis compared to the same period a year ago [20][21] - Adjusted EBITDA was $871,000,000, an increase of $45,000,000 or 5% year over year [21] - Adjusted operating cash flow was $442,000,000, reflecting strong operational performance [21] Business Line Data and Key Metrics Changes - Salix revenues were $627,000,000, an increase of 12% compared to the same period last year, driven by favorable net pricing and strong volume performance [23] - Solta revenues were $128,000,000, an increase of 25% on a reported basis and 26% on an organic basis, primarily fueled by South Korea [25] - The diversified segment revenues were $219,000,000, a decrease of 13% compared to the same period a year ago, impacted by one-time pricing adjustments in neurology and dermatology [27] Market Data and Key Metrics Changes - EMEA achieved 6% organic growth in the second quarter, marking its tenth consecutive quarter of organic growth [11] - Canada experienced double-digit growth driven by promoted products, with a 12% increase in the top line [24] - LATAM's performance was softer due to ongoing macroeconomic challenges and partial channel destocking [24] Company Strategy and Development Direction - The company is focused on unlocking value, growth, and optimizing its capital structure, with a commitment to R&D and business development [30][31] - The acquisition of Direct Corporation aims to enhance the development of treatments for alcohol hepatitis, showcasing the company's commitment to addressing unmet medical needs in hepatology [17][18] - The company continues to evaluate opportunities to maximize returns for stakeholders and improve its capital structure [7][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute strategic priorities and deliver value for stakeholders, despite a more uncertain macro environment [4][20] - The company reaffirmed its full-year 2025 guidance for revenue and adjusted EBITDA, indicating a positive outlook for the remainder of the year [5][30] Other Important Information - The company completed a $7,900,000,000 debt refinancing, extending maturities and improving its capital structure [7][28] - The company has settled nine more opt-out cases year to date, with 11 remaining, and received communication from the IRS that a significant legal matter has concluded without negative cash flow implications [19] Q&A Session Summary Question: Share buybacks and DTC efforts for XIFAXAN - Management confirmed that share buybacks are still a possibility but have been deprioritized in favor of reinvestment in the business [36][37] - The focus for DTC investments is currently on the OHE indication, with significant growth observed in both indications [38][39] Question: Rifaximin franchise and SSD trials - Management confirmed that lactulose background therapy is allowed in the SSD trials and emphasized the potential patient population for the SSD product [42][44] - The possibility of XIFAXAN being available over-the-counter has not been considered at this time [45] Question: XIFAXAN ROA headwinds and revenue discrepancies - Management discussed ongoing negotiations regarding XIFAXAN and the potential impact of IRA on pricing, emphasizing the importance of presenting their case [48][49] - Discrepancies between revenue growth and prescription growth for RELISTOR and TRULANCE were attributed to favorable gross-to-net adjustments [51] Question: Direct Corporation acquisition details - Management expressed enthusiasm about the Direct Corporation acquisition and its potential to address significant unmet needs in hepatology [53][54] Question: Rifaximin SSD differentiation and head-to-head trials - Management stated that the SSD formulation is different in dosage and action compared to existing formulations, and no head-to-head trials are planned at this time [58][59] Question: IRA negotiations and price points - Management acknowledged the ongoing negotiations and the potential for significant price cuts, while emphasizing their strategy to minimize the impact [62][66]